linjc16/ctgov huggingface dataset:
Comparison of Postoperative Pain Between Patients Received Primary and Repeated Caesarean Section

Study Overview
=================
Brief Summary
-----------------
To everyone knows, more and more patients received repeated caesarean section in China. However, at present it is not known what is it like about their postoperative pain intensity, and is it different from those patients who received primary caesarean section. Thus through postoperative follow-up, the current study aimed to investigate and compare the postoperative pain between patients received primary and repeated caesarean section.

Detailed Description
-----------------
According to whether or not to receive repeated caesarean patients were grouped into group P or group R. For all maternal,standardized epidural anesthesia and caesarean section were performed. Then the pain VAS scores and Ramsay scores at 4h, 8h, 12h, 24h and 48h after the surgery were recorded. And sleep quality at 1 day and 2 day after the surgery were recorded. In addition, pain situation at 1 week and 4 weeks after the surgery was followed up.

Official Title
-----------------
Comparison of Postoperative Pain Between Patients Received Primary and Repeated Caesarean Section

Conditions
-----------------
Caesarean Section

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: single birth full-term pregnancy in accordance with cesarean section indications transverse incision of lower uterine segment Exclusion Criteria: history of dementia, psychiatric illness or any diseases of central nervous system accompanying liver or kidney function deficiency alcoholism and drug dependence patients previously included in this study or currently included in the other clinical study patients who have second surgery during the study period difficult to follow up or patients with poor compliance history of chronic pain

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group P<br>patients who received primary caesarean section | |
| Group R<br>patients who received repeated caesarean section | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain VAS at 4, 8, 12, 24 and 48 hours after the surgery |  | At 4, 8, 12, 24 and 48 hours after the surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain intensity at 3 to 7 days after the surgery |  | At 3 to 7 days after the surgery | 
| Pain intensity at 4 weeks after the surgery |  | At 4 weeks after the surgery |
Efficacy of Omalizumab as Add on Therapy for Minority Patients With Moderate to Severe Asthma

Study Overview
=================
Brief Summary
-----------------
This study will be a randomized, placebo controlled, double blind study to measure the safety and efficacy of a new, injectable asthma medication, omalizumab, in a group of minority with moderate to severe asthma who are not adequately controlled with use of inhaled or oral steroids. Primary endpont will be change in asthma symptom utility index. Secondary endpoints will be changes in asthma Quality of life, asthma exacerbation rate, and lung function over the 12 week treatment period.

Official Title
-----------------
Efficacy of Omalizumab as Add on Therapy for Minority Patients With Moderate to Severe Asthma

Conditions
-----------------
Asthma

Intervention / Treatment
-----------------
* Drug: Omalizumab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18-30 Minority Patients Moderate or Severe allergic asthma (as defined by the National Asthma Education and Prevention Guidelines(7)]. Allergic asthma will be defined as elevated IgE level (> 100 IU/ml) and skin test sensitivity to at least one common aeroallergen asthma control score greater than 1.5 (5) at randomization visit with use of equivalent of at least 1000 mcg fluticasone daily or systemic steroid use FEV1 50-90% predicted at screening and randomization visit Exclusion Criteria: Active smoking within one year and/or greater than 10-pack year history of smoking Women of childbearing age must be using effective contraception Malignancy diagnosed within the past 5 years Underlying lung disease other than asthma Inability to comply with study protocol

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: omaluzimab<br> | Drug: Omalizumab<br>* injectable medication<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Asthma symptom utility index |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Secondary endpoints will be changes in asthma Quality of Life, asthma exacerbation rate, and lung function over the 12 week treatmet period. |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Xolair, omalizumab, severe asthma, moderate asthma, injectable asthma medication
Postoperative Quality Recovery Scale (PQRS)

Study Overview
=================
Brief Summary
-----------------
Recovery following general anesthesia and surgery is a complex issue confounded by the type of surgery, surgical care, inflammation, different anesthetic drugs and techniques, patient co-morbidities, and differing patient and clinician perceptions of what constitutes good recovery. In this observational study, quality of recovery and patient satisfaction will be measured using the Postoperative Quality Recovery Scale (PQRS). This tool includes six domains of recovery: physiological, nociceptive (pain and nausea), emotive (anxiety and depression), functional recovery (return of activities of daily living), self-assessed recovery, and cognitive recovery.

Official Title
-----------------
Measuring Recovery in Patients Undergoing Major Abdominal, Thoracic, and Arthroplasty Surgery Using an Enhanced Recovery Program.

Conditions
-----------------
Surgery, Recovery

Intervention / Treatment
-----------------
* Other: Postoperative Quality Recovery Scale (PQRS)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: elective major abdominal, thoracic, and arthroplasty surgery Exclusion Criteria: Poor comprehension of English or French
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Elective major abdominal, thoracic, and arthroplasty surgery<br>All consenting patients scheduled for elective major abdominal, thoracic, and arthroplasty surgery will be followed for 8 weeks after surgery to measure the quality of recovering using the PQRS. | Other: Postoperative Quality Recovery Scale (PQRS)<br>* The PQRS is completed prior to surgery to provide baseline values, and then repeated at different intervals: 15 minutes, 40 minutes, 1 and 3 days, and 4-8 weeks after the completion of surgery. Recovery is broadly defined as return to baseline or better.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of recovery (return to baseline or better) in the cognitive domain of the PQRS |  | postoperative day 3 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
thoracic, arthroplasty, abdominal
Totally Implantable Catheters in Pediatric Hematology-oncology: a Study on Infectious Complications

Study Overview
=================
Brief Summary
-----------------
This is a retrospective analysis of infection on catheters of pediatric oncology patients.

Conditions
-----------------
Infections

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients admitted between Jan/2008 and Dec/2009
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Prevalence of Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) Following Squamous Cell Carcinomas of the Oropharynx Treatment by Combined Chemoradiotherapy

Study Overview
=================
Brief Summary
-----------------
The study's aim is to determinate the prevalence of obstructive sleep apnea hypopnea syndrome after treatment by combined chemoradiotherapy in a locally advanced stages treated population of oropharyngeal cancer. Indeed, the level of knowledge about the consequences of oropharyngeal cancer treatment on sleep quality remains poor but the few studies published on the subject suggest an increased risk of development of OSAHS for these patients.

Official Title
-----------------
Prevalence of Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) Following Squamous Cell Carcinomas of the Oropharynx Treatment by Combined Chemoradiotherapy

Conditions
-----------------
Obstructive Sleep Apnea-hypopnea, Oropharyngeal Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age> 18 years old Performance Status 0-2 Squamous cell carcinoma of the oropharynx treated with concomitant chemoradiotherapy Treatment termination time greater than 6 months at inclusion Tumor classification (American Joint Committee on Cancer 8th) T2-T4 N0-N3 Patient in complete remission at inclusion patient's consent's obtained after information Exclusion Criteria: Previous treatment for upper aerodigestive tract cancer Incomplete radiotherapyTreatment Neurological pathology wich may affect the functions of the upper aerodigestive tract Pregnant or breastfeeding woman Unweaned alcoholism Tracheotomized patient at the time of the study Patient under protection: subjects with guardianship or under law protection No health insurance coverage

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of obstructive sleep apnea hypopnea syndrome after treatment by combined chemoradiotherapy. | Number of patients with obstructive sleep apnea hypopnea syndrome after treatment combined chemoradiotherapy. | Day 28 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Severity of OSAHS as a function of the post-therapeutic delay. | Value of the AHI as a function of the post-therapeutic delay which corresponds to the delay compared to the end of the curative treatment carried out for squamous cell carcinoma of the oropharynx. It is obtained after the inclusion visit and the realization of the polygraphy with the IAH score. OSAHS is mild (if IAH ≥ 5 / h and <15 / h), moderate (if IAH ≥ 15 / h and ≤ 30 / h) or severe (if IAH> 30 / h) | Day 28 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
combined chemoradiotherapy
Weaning From Mechanical Ventilation Guided by Lung Ultrasound (Brazilian WEANLUS)

Study Overview
=================
Brief Summary
-----------------
The present study aims to evaluate the impact of a weaning strategy based on identification of early signs of respiratory distress by lung ultrasound and the consequent implementation of a clinical optimization protocol as compared to usual care.

Official Title
-----------------
Weaning From Mechanical Ventilation Guided by Lung Ultrasound (Brazilian WEANLUS)

Conditions
-----------------
Acute Respiratory Failure

Intervention / Treatment
-----------------
* Other: weaning guided by LUS (lung ultrasound)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Mechanically ventilated >48h Exclusion Criteria: Moderate/Severe COPD Spinal cord lesion Neuromuscular disease (previous) Lung fibrosis Tracheostomy Heart failure (EF<50%) Lung/pleural cancer inadequate windowfor LUS

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: usual care<br>Weaning as protcolised by the units' daily practice (SBT) | |
| Experimental: Weaning guided by lung ultrasound<br>Predictive early signs of respiratory distress are assessed by lung ultrasound and if found will trigger protocolised intervention (eg- fluid balance,diuretics, thoracocentesis) | Other: weaning guided by LUS (lung ultrasound)<br>* Predictive early signs of respiratory distress are assessed by lung ultrasound (LUS score >14) and if present will trigger protocolised intervention (eg- fluid balance,diuretics, thoracocentesis, antibiotics when required [CPIS>6], hemglobin>8g/dl triggers transfusion)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Respiratory distress requiring re-intubation or non-invasive ventilation |  | 48hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 28-day mortality |  | 28 days | 
| Hospital Mortality |  | Hospital death/discharge (up to 60 days) | 
| Adverse events | Renal dysfunction, complications of thoracocentesis, hydro-electrolite changes, hypotension | 48h | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
mechanical ventilation, weaning, acute respiratory failure, weaning failure, lung ultrasound
Efficacy of LNG-IUS for Treatment of Non-atypical Endometrial Hyperplasia in Perimenopausal Women

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare the efficacy of the Levonorgestrel releasing Intrauterine System (Mirena) and Norethisterone Acetate for treatment of non-atypical endometrial hyperplasia in perimenopausal women.

Official Title
-----------------
LNG-IUS or Norethisterone Acetate for Treatment of Non-atypical Endometrial Hyperplasia in Perimenopausal Women

Conditions
-----------------
Endometrial Hyperplasia

Intervention / Treatment
-----------------
* Drug: LNG-IUS; Mirena; Bayer Schering Pharma Oy, Finland
* Drug: Norethisterone Acetate tablets


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with histologically confirmed simple or complex endometrial hyperplasia without atypia Exclusion Criteria: Endometrial hyperplasia with atypia Other pathology e.g. patients with fibroids of any size, genital infection, adnexal abnormality.

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: LNG-IUS<br>Release rate of 20µg Levonorgestrel(Mirena, Bayer Schering Pharma Oy, Finland) per day with one year follow up. | Drug: LNG-IUS; Mirena; Bayer Schering Pharma Oy, Finland<br>* Initial release rate of 20µg Levonorgestrel per day for one year follow up.<br>|
| Active Comparator: Norethisterone Acetate<br>Norethisterone Acetate tablets at a dose of 5 mg three times daily (15mg/day) for 3 weeks over three months.With persistence of endometrial hyperplasia, the treatment is repeated for another 3 months | Drug: Norethisterone Acetate tablets<br>* Norethisterone Acetate tablets at a dose of 5 mg three times daily (15mg/day) for 3 weeks over three months.With persistence of endometrial hyperplasia, the treatment is repeated for another 3 months<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in endometrial histopathology pattern from endometrial hyperplasia into regression status. |  | At 3 and 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to achieve complete regression |  | During the follow up period at 3,6,12 months after treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Endometrial hyperplasia,, LNG-IUS,, Progestin
Atrial Fibrillation Recurrence After Cryoballoon Ablation

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to evaluate the mechanisms of recurrent atrial fibrillation after cryoballoon ablation using the Arctic Front Ablation System. For those with pulmonary vein reconnection, specific sites of reconnection will be evaluated with left atrial intracardiac echo (ICE) guidance. The Achieve mapping catheter will be evaluated head-to-head with our current method of ICE-guided recordings from a conventional mapping catheter with high output pulmonary venous pacing.

Official Title
-----------------
Mechanisms and Patterns of Atrial Fibrillation Recurrence After Cryoballoon Ablation

Conditions
-----------------
Atrial Fibrillation

Intervention / Treatment
-----------------
* Other: Use of the Achieve catheter followed by ICE-guided mapping catheter


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing re-do catheter ablation procedure after index procedure with cryoballoon ablation At least 18 years old Able to read and understand informed consent Exclusion Criteria: Unable to give informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Recurrent Atrial Fibrillation<br> | Other: Use of the Achieve catheter followed by ICE-guided mapping catheter<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Presence or absence of pulmonary vein isolation or reconnection |  | During repeat cryoballoon ablation procedure | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Atrial Fibrillation, Cryoballoon Ablation
Safety and Efficacy of AAE581 in Postmenopausal Women With Osteoporosis

Study Overview
=================
Brief Summary
-----------------
This study will test the safety and efficacy of AAE581 in increasing Lumbar Spine bone mineral density (BMD) at 12 months, by Dexa-scan (DXA) in postmenopausal women with osteoporosis.

Official Title
-----------------
Safety and Efficacy of AAE581 in Postmenopausal Women With Osteoporosis

Conditions
-----------------
Osteoporosis

Intervention / Treatment
-----------------
* Drug: AAE581


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: BMD T Score between -2 to -3.5 50-75 years old Exclusion Criteria: Urolithiasis Bisphosphonates Other protocol-defined inclusion/exclusion criteria may apply.

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: AAE581|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Lumbar spine BMD and total hip BMD after 1 year treatment |  |  | 
| Safety and tolerability of one year treatment with different doses |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Effect of the different doses on BMD of lumbar spine, femoral neck, total hip, forearm and total body |  |  | 
| Effect of the different doses on markers for bone formation and bone resorption |  |  | 
| Structural information on cortical and trabecular bone at different anatomic sites after 6 and 12 months of treatment |  |  | 
| Histological information on bone biopsy after 12 months of treatment |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
osteoporosis/osteopenia, BMD, postmenopausal